Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-05

FDA Approved: CHILDRENS XYZAL ALLERGY — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Children's XYZAL Allergy (levocetirizine dihydrochloride) from Chattem, Inc., signaling a label update or expans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CHILDRENS XYZAL ALLERGY (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for CHILDRENS XYZAL ALLERGY (LEVOCETIRIZINE DIHYDROCHLORIDE)